The why, what and when of the Joint Clinical Assessment

The Joint Clinical Assessment, which came into effect in the European Union in January 2025, represents a fundamental shift in the health technology assessment (HTA) decision-making process. Since 12 January 2025, new oncology medicines and advanced therapy medicinal products (ATMPs) have been subject to the JCA, which is a key mechanism within the Health Technology […]